Artmış Lipid Seviyeleri ve Meme Kanseri

Yıl 2019, Cilt: 4 Sayı: 2, 128 - 138, 30.06.2019

Ömer Parlak Servet Kocaöz

https://doi.org/10.26453/otjhs.463786

Öz

Meme kanseri, hem
gelişmiş hem de gelişmekte olan ülkelerde kadınlarda görülen en sık kanserdir.
Metabolik heterojenite tüm kanserlerde mevcut olabilir. Dislipidemi, bağımsız
olarak meme kanseri gelişimi ile ilişkilidir. Bu çalışma, çalışma grubundaki
100 meme kanseri hastasından ve kontrol grubu olarak adlandırılan 100 benzer
normal kadınlardan alınan serum örnekleri üzerinde yapıldı. Herhangi bir tedavi
uygulamadan önce çalışma grubu ve kontrol grubu üzerinde lipit paterni
çalışmaları yapıldı. Toplanan serum örnekleri Total kolesterol (TC), HDL, LDL
ve Trigliserit konsantrasyonları açısından incelenmiştir. Çalışma grubunda en
genç hasta 35 yaşında, en yaşlı hasta 83 yaşında idi. Ortalama yaş 58,41 ±
11,01 yıldı. Kontrol grubunda en genç hasta 30 yaşındaydı ve en yaşlı hasta 80
yaşındaydı. TC, LDL, TG seviyeleri bütün evrelerde artmış olarak bulundu ve
C-ERB-B2 pozitifliğinde de benzer olan artmıştır. Çalışmamız lipid düzeyleri
ile meme kanseri arasındaki ilişkiyi desteklemektedir. Bununla birlikte, bir
marker olarak kullanılmak üzere, prospektif de dahil olmak üzere çoklu merkez
çalışmalarına ihtiyaç duyulmaktadır.

Anahtar Kelimeler

Lipid düzeyi, Meme Kanseri

Increased Lipids Levels and Breast Cancer

Öz

Breast
cancer is the top cancer in women both in the developed and the developing
world. Metabolic heterogeneity may be present in all cancers. Dyslipidemia is
independently associated with the development of breast cancer. The present
study was carried out on serum samples from 100 breast cancer patients named
study group and 100 similar age normal women named control group. Lipid pattern
studies were carried out on study group and control group before any treatment.
The   serum   samples  
so   collected   were  
examined   for   Total cholesterol  (TC), 
High  density  lipoprotein 
cholesterol  (HDL),  Low density 
lipoprotein  cholesterol  (LDL) and 
Triglyceride  (TG)  concentrations. In the study group the
youngest patient was of 35 years old and oldest patient was of 83 years. Mean
age was 58.41±11.01 years. In the control group, the youngest patient was of 30
years and oldest patient was of 80 years. TC, LDL, TG levels increased in all
grades, which is similar in the of C-ERB-B2 positive status. Our study supports
the relationship between increased lipid levels and breast cancer. However,
there is a need for multiple center studies, including prospective, to be used
as a marker.

Anahtar Kelimeler

Lipid level, Breast cancer

Kaynakça

• 1. World Health Organization (WHO). 11.06.2018 Available from: http://www.who.int/cancer/detection/breastcancer/en/
• 2. Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin 2017; 67:7.
• 3. Martinez-Outschoorn UE, Peiris-Pages M, Pestell RG, Sotgia F, Lisanti MP. Cancer metabolism: a therapeutic perspective. Nat Rev Clin Oncol. 2017; 14(1):11- 31.
• 4. Cibeira GH, Giacomazzi J, Aguiar E, Schneider S, Ettrich B, CI DES, Camey S, Caleffi M, Weber B, Ashton-Prolla P, et al. Apolipoprotein E genetic polymorphism, serum lipoprotein levels and breast cancer risk: a case-control study. Mol Clin Oncol. 2014;2(6):1009–15.
• 5. His M, Dartois L, Fagherazzi G, Boutten A, Dupre T, Mesrine S, Boutron-Ruault MC, Clavel-Chapelon F, Dossus L. Associations between serum lipidsand breast cancer incidence and survival in the E3N prospective cohort study. Cancer Causes Control. 2017;28(1):77–88.
• 6. Gershuni V, Li YR, Williams AD, So A, Steel L, Carrigan E, Tchou J. Breast cancer subtype distribution is different in normal weight, overweight, and obese women. Breast Cancer Res Treat. 2017;
• 7. Agresti R, Meneghini E, Baili P, Minicozzi P, Turco A, Cavallo I, Funaro F, Amash H, Berrino F, Tagliabue E, et al. Association of adiposity, dysmetabolisms, and inflammation with aggressive breast cancer subtypes: a cross-sectional study. Breast Cancer Res Treat. 2016;157(1): 179–89.
• 8. Kwan ML, Kroenke CH, Sweeney C, Bernard PS, Weltzien EK, Castillo A,Factor RE, Maxfield KS, Stijleman IJ, Kushi LH, et al. Association of high obesity with PAM50 breast cancer intrinsic subtypes and gene expression. BMC Cancer. 2015;15:278.
• 9. Balaban S, Lee LS, Schreuder M, Hoy AJ. Obesity and cancer progression: is there a role of fatty acid metabolism? Biomed Res Int. 2015;2015:274585.
• 10. Saavedra-Garcia P, Nichols K, Mahmud Z, Fan LY, Lam EW. Unravelling the role of fatty acid metabolism in cancer through the FOXO3-FOXM1 axis. Mol Cell Endocrinol. 2017. S0303-7207(17):30016–3.
• 11. Li X, Tang H, Wang J, Xie X, Liu P, Kong Y, Ye F, Shuang Z, Xie Z, Xie X. The effect of preoperative serum triglycerides and high-density lipoprotein-cholesterol levels on the prognosis of breast cancer. Breast (Edinburgh,Scotland). 2017;32:1–6.
• 12. Warner M, Gustafsson JA. On estrogen, cholesterol metabolism, and breast cancer. N Engl J Med. 2014;370(6):572–3.
• 13. His M, Zelek L, Deschasaux M, Pouchieu C, Kesse-Guyot E, Hercberg S, Galan P, Latino-Martel P, Blacher J, Touvier M. Prospective associations between serum biomarkers of lipid metabolism and overall, breast and prostate cancer risk. Eur J Epidemiol. 2014;29(2):119–32.
• 14. Furberg AS, Veierod MB, Wilsgaard T, Bernstein L, Thune I. Serum high-density lipoprotein cholesterol, metabolic profile, and breast cancer risk. J Natl Cancer Inst. 2004;96(15):1152–60.15. Furberg AS, Jasienska G, Bjurstam N, Torjesen PA, Emaus A, Lipson SF, Ellison PT, Thune I. Metabolic and hormonal profiles: HDL cholesterol as a plausible biomarker of breast cancer risk. The Norwegian EBBA study.
• 16. Cancer Epidemiol Biomark Prev. 2005;14(1):33–40. Flote VG, Frydenberg H, Ursin G, Iversen A, Fagerland MW, Ellison PT, Wist EA, Egeland T, Wilsgaard T, McTiernan A, et al. High-density lipoprotein-cholesterol, daily estradiol and progesterone, and mammographic density phenotypes in premenopausal women. Cancer Prev Res (Phila). 2015;8(6): 535–44.
• 17. Emaus A, Veierod MB, Tretli S, Finstad SE, Selmer R, Furberg AS, Bernstein L, Schlichting E, Thune I. Metabolic profile, physical activity, and mortality in breast cancer patients. Breast Cancer Res Treat. 2010;121(3):651–60.
• 18. Fan Y, Ding X, Wang J, Ma F, Yuan P, Li Q, Zhang P, Xu B. Decreased serum HDL at initial diagnosis correlates with worse outcomes for triple-negativebreast cancer but not non-TNBCs. Int J Biol Markers. 2015;30(2):e200–7.
• 19. Flote VG, Vettukattil R, Bathen TF, Egeland T, McTiernan A, Frydenberg H, Husoy A, Finstad SE, Lomo J, Garred O, et al. Lipoprotein subfractions by nuclear magnetic resonance are associated with tumor characteristics in breast cancer. Lipids Health Dis. 2016;15:56.
• 20. Gillet CE, Happerfield LC. Breast cancer – from clinic to laboratory. Br J Biomed Sci. 1997;54:47–56.
• 21. Henerson MM. Nutritional aspects of breast cancer. Cancer. 1995;76:2053–58.
• 22. Kelsey JL, Gammon MD, John EM. Reproductive factors and breast cancer. Cancer Epidemiol Res. 1993;15:36–47.
• 23. Lai LC. Metabolism of dehydroepiandrosterone sulfate by breast cysts:possible role in the development of breast cancer. Cancer Detect Prev. 1995;19:441–45.24. A Ray, SL Dayalu Naik, RS Rautela, BK Sharma. Serum lipids, lipoproteins and sex hormone binding globulin in breast cancer. J Clin Biochem. 2001;6(1):101-05.
• 25. X. Li, H. Tang, J. Wang, X. Xie, P. Liu, Y. Kong et al. The effect of preoperative serum triglycerides and high-density lipoprotein-cholesterol levels on the prognosis of breast cancer The Breast; 32, April 2017, 1-6
• 26. Bhat SA, Mir MR, Majid S, Reshi AA, Husain I, Hassan T, et al. Serum Lipid Profile of Breast Cancer Patients in Kashmir. J Invest Biochem. 2013;2(1):26-31.
• 27. Manuela Gago-Dominguez, Manuel Calaza, Victor Muñoz-Garzon, Maria Elena Martinez and Jose Esteban Castelao American Association for Cancer Research DOI: 10.1158/1538-7445.AM2017-2269 July 2017.
• 28. Uzma Raza, Mahay Rookh Asif, Asif Bin Rehman, and Aminuddin Sheikh Hyperlipidemia and hyper glycaemia in Breast Cancer Patients is related to disease stage. Pakistan Journal of Medical Sciences; 2018 Jan-Feb; 34(1): 209–14. doi: 10.12669/pjms.341.14841